Halozyme Therapeutics (HALO)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.34 (+0.71%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Halozyme Therapeutics (HALO)
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Key Insights

Critical company metrics and information
  • Share Price

    $48.40
  • Market Cap

    $6.16 Billion
  • Total Outstanding Shares

    127.23 Million Shares
  • Total Employees

    373
  • Dividend

    No dividend
  • IPO Date

    March 12, 2004
  • SIC Description

    Biological Products, (no Disgnostic Substances)
  • Homepage

    https://www.halozyme.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities, Continuing$-300.49 Million
Net Cash Flow From Operating Activities$402.95 Million
Net Cash Flow From Investing Activities$-300.49 Million
Net Cash Flow From Financing Activities$-222.37 Million
Net Cash Flow From Financing Activities, Continuing$-222.37 Million
Net Cash Flow$-119.91 Million
Net Cash Flow From Operating Activities, Continuing$402.95 Million
Net Cash Flow, Continuing$-119.91 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Revenues$947.36 Million
Basic Average Shares$379.94 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Cost Of Revenue$169.66 Million
Income Tax Expense/Benefit$87.63 Million
Net Income/Loss Attributable To Parent$392.47 Million
Net Income/Loss$392.47 Million
Other Operating Expenses$71.05 Million
Basic Earnings Per Share$3.07
Diluted Earnings Per Share$3.02
Research and Development$79.94 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Average Shares$258.19 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Benefits Costs and Expenses$467.26 Million
Gross Profit$777.70 Million
Net Income/Loss Available To Common Stockholders, Basic$392.47 Million
Selling, General, and Administrative Expenses$149.69 Million
Operating Income/Loss$477.01 Million
Income/Loss From Continuing Operations Before Tax$480.09 Million
Costs And Expenses$470.35 Million
Income/Loss From Continuing Operations After Tax$392.47 Million
Operating Expenses$300.69 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities And Equity$2.12 Billion
Equity Attributable To Noncontrolling Interest$0.00
Liabilities$1.67 Billion
Equity$452.70 Million
Other Current Assets$964.51 Million
Long-term Debt$1.50 Billion
Fixed Assets$39.98 Million
Noncurrent Liabilities$1.56 Billion
Other Current Liabilities$96.42 Million
Other Non-current Liabilities$52.36 Million
Assets$2.12 Billion
Prepaid Expenses$31.05 Million
Equity Attributable To Parent$452.70 Million
Inventory$131.41 Million
Accounts Payable$12.40 Million
Current Assets$1.13 Billion
Intangible Assets$419.59 Million
Current Liabilities$108.81 Million
Noncurrent Assets$991.05 Million
Other Non-current Assets$531.49 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.